Portal de Periódicos da CAPES

Pellagra: will we see it more frequently?

2008; Wiley; Volume: 23; Issue: 3 Linguagem: Inglês

10.1111/j.1468-3083.2008.02883.x

1468-3083

Gökhan Okan, Serpil Yaylacı, Suha Alzafer,

Vitamin C and Antioxidants Research

Journal of the European Academy of Dermatology and VenereologyVolume 23, Issue 3 p. 365-366 Pellagra: will we see it more frequently? G Okan, Corresponding Author G Okan Dermatology Department Correspondence: G Okan. E-mail: [email protected]Search for more papers by this authorS Yaylaci, S Yaylaci Emergency DepartmentSearch for more papers by this authorS Alzafer, S Alzafer Pulmonology Department, Acibadem Bakirkoy Hospital, Istanbul, TurkeySearch for more papers by this author G Okan, Corresponding Author G Okan Dermatology Department Correspondence: G Okan. E-mail: [email protected]Search for more papers by this authorS Yaylaci, S Yaylaci Emergency DepartmentSearch for more papers by this authorS Alzafer, S Alzafer Pulmonology Department, Acibadem Bakirkoy Hospital, Istanbul, TurkeySearch for more papers by this author First published: 09 February 2009 https://doi.org/10.1111/j.1468-3083.2008.02883.xCitations: 9 DOI: 10.1111/j.1468-3083.2008.02883.x Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Karthikeyan K, Thappa DM. Pellagra and skin. Int J Dermatol 2002; 41: 476–481. 2 Isaac S. The gauntlet of pellagra. Int J Dermatol 1998; 37: 599. 3 Darvay A, Basarab T, McGregor JM, Russell-Jones R. Isoniazid induced pellagra despite pyridoxine supplementation. Clin Exp Dermatol 1999; 24: 167–169. 4 Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Artritis Rheum 2007; 57: 756–761. 5 Keane J, Gershan S, Wise RP et al . Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001; 345: 1098–1104. Citing Literature Volume23, Issue3March 2009Pages 365-366 ReferencesRelatedInformation